Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown and increased IL-6 release

Ermina Bach; Bent Roni Ranghøj Nielsen; Mikkel Vendelbo; Andreas Buch Møller; Niels Jessen; Mads Buhl; Thomas Krusenstjerna- Hafstrøm; Lars Holm; Steen B. Pedersen; Henriette Pilegaard; Rasmus Sjørup Biensø; Jens Otto Lunde Jørgensen; Niels Møller

doi:10.2337/db13-0138

Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown and increased IL-6 release

Ermina Bach, Bent Roni Ranghøj Nielsen, Mikkel Vendelbo, Andreas Buch Møller, Niels Jessen, Mads Buhl, Thomas Krusenstjerna- Hafstrøm, Lars Holm, Steen B. Pedersen, Henriette Pilegaard, Rasmus Sjørup Biensø, Jens Otto Lunde Jørgensen, Niels Møller

Molecular Integrative Physiology

31 Citations (Scopus)

Abstract

Tumor necrosis factor-a (TNF-a) has widespread metabolic actions. Systemic TNF-a administration, however, generates a complex hormonal and metabolic response. Our study was designed to test whether regional, placebo-controlled TNF-a infusion directly affects insulin resistance and protein breakdown. We studied eight healthy volunteers once with bilateral femoral vein and artery catheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp. One artery was perfused with saline and one with TNF-a. During the clamp, TNF-a perfusion increased glucose arteriovenous differences (0.91 6 0.17 vs. 0.74 6 0.15 mmol/L, P = 0.012) and leg glucose uptake rates. Net phenylalanine release was increased by TNF-a perfusion with concomitant increases in appearance and disappearance rates. Free fatty acid kinetics was not affected by TNF-a, whereas interleukin-6 (IL-6) release increased. Insulin and protein signaling in muscle biopsies was not affected by TNF-a. TNF-a directly increased net muscle protein loss, which may contribute to cachexia and general protein loss during severe illness. The finding of increased insulin sensitivity, which could relate to IL-6, is of major clinical interest and may concurrently act to provide adequate tissue fuel supply and contribute to the occurrence of systemic hypoglycemia. This distinct metabolic feature places TNF-a among the rare insulin mimetics of human origin.

Original language	English
Journal	Diabetes
Volume	62
Issue number	12
Pages (from-to)	4023-4029
Number of pages	8
ISSN	0012-1797
DOIs	https://doi.org/10.2337/db13-0138
Publication status	Published - Dec 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/db13-0138

http://dx.doi.org/10.2337/db13-0138

Fingerprint

Dive into the research topics of 'Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown and increased IL-6 release'. Together they form a unique fingerprint.

Cite this

Bach, E., Nielsen, B. R. R., Vendelbo, M., Møller, A. B., Jessen, N., Buhl, M., Hafstrøm, T. K., Holm, L., Pedersen, S. B., Pilegaard, H., Biensø, R. S., Jørgensen, J. O. L., & Møller, N. (2013). Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown and increased IL-6 release. Diabetes, 62(12), 4023-4029. https://doi.org/10.2337/db13-0138

Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg : increased insulin sensitivity, increased net protein breakdown and increased IL-6 release. / Bach, Ermina; Nielsen, Bent Roni Ranghøj; Vendelbo, Mikkel et al.

In: Diabetes, Vol. 62, No. 12, 12.2013, p. 4023-4029.

Research output: Contribution to journal › Journal article › Research › peer-review

Bach, E, Nielsen, BRR, Vendelbo, M, Møller, AB, Jessen, N, Buhl, M, Hafstrøm, TK, Holm, L, Pedersen, SB, Pilegaard, H, Biensø, RS, Jørgensen, JOL & Møller, N 2013, 'Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown and increased IL-6 release', Diabetes, vol. 62, no. 12, pp. 4023-4029. https://doi.org/10.2337/db13-0138

@article{dc62b1ceaecf4d4bb38c9b6ca303c249,

title = "Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown and increased IL-6 release",

abstract = "Tumor necrosis factor-a (TNF-a) has widespread metabolic actions. Systemic TNF-a administration, however, generates a complex hormonal and metabolic response. Our study was designed to test whether regional, placebo-controlled TNF-a infusion directly affects insulin resistance and protein breakdown. We studied eight healthy volunteers once with bilateral femoral vein and artery catheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp. One artery was perfused with saline and one with TNF-a. During the clamp, TNF-a perfusion increased glucose arteriovenous differences (0.91 6 0.17 vs. 0.74 6 0.15 mmol/L, P = 0.012) and leg glucose uptake rates. Net phenylalanine release was increased by TNF-a perfusion with concomitant increases in appearance and disappearance rates. Free fatty acid kinetics was not affected by TNF-a, whereas interleukin-6 (IL-6) release increased. Insulin and protein signaling in muscle biopsies was not affected by TNF-a. TNF-a directly increased net muscle protein loss, which may contribute to cachexia and general protein loss during severe illness. The finding of increased insulin sensitivity, which could relate to IL-6, is of major clinical interest and may concurrently act to provide adequate tissue fuel supply and contribute to the occurrence of systemic hypoglycemia. This distinct metabolic feature places TNF-a among the rare insulin mimetics of human origin.",

author = "Ermina Bach and Nielsen, {Bent Roni Rangh{\o}j} and Mikkel Vendelbo and M{\o}ller, {Andreas Buch} and Niels Jessen and Mads Buhl and Hafstr{\o}m, {Thomas Krusenstjerna-} and Lars Holm and Pedersen, {Steen B.} and Henriette Pilegaard and Biens{\o}, {Rasmus Sj{\o}rup} and J{\o}rgensen, {Jens Otto Lunde} and Niels M{\o}ller",

year = "2013",

month = dec,

doi = "10.2337/db13-0138",

language = "English",

volume = "62",

pages = "4023--4029",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association",

number = "12",

}

TY - JOUR

T1 - Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo controlled bilaterally infused human leg

T2 - increased insulin sensitivity, increased net protein breakdown and increased IL-6 release

AU - Bach, Ermina

AU - Nielsen, Bent Roni Ranghøj

AU - Vendelbo, Mikkel

AU - Møller, Andreas Buch

AU - Jessen, Niels

AU - Buhl, Mads

AU - Hafstrøm, Thomas Krusenstjerna-

AU - Holm, Lars

AU - Pedersen, Steen B.

AU - Pilegaard, Henriette

AU - Biensø, Rasmus Sjørup

AU - Jørgensen, Jens Otto Lunde

AU - Møller, Niels

PY - 2013/12

Y1 - 2013/12

N2 - Tumor necrosis factor-a (TNF-a) has widespread metabolic actions. Systemic TNF-a administration, however, generates a complex hormonal and metabolic response. Our study was designed to test whether regional, placebo-controlled TNF-a infusion directly affects insulin resistance and protein breakdown. We studied eight healthy volunteers once with bilateral femoral vein and artery catheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp. One artery was perfused with saline and one with TNF-a. During the clamp, TNF-a perfusion increased glucose arteriovenous differences (0.91 6 0.17 vs. 0.74 6 0.15 mmol/L, P = 0.012) and leg glucose uptake rates. Net phenylalanine release was increased by TNF-a perfusion with concomitant increases in appearance and disappearance rates. Free fatty acid kinetics was not affected by TNF-a, whereas interleukin-6 (IL-6) release increased. Insulin and protein signaling in muscle biopsies was not affected by TNF-a. TNF-a directly increased net muscle protein loss, which may contribute to cachexia and general protein loss during severe illness. The finding of increased insulin sensitivity, which could relate to IL-6, is of major clinical interest and may concurrently act to provide adequate tissue fuel supply and contribute to the occurrence of systemic hypoglycemia. This distinct metabolic feature places TNF-a among the rare insulin mimetics of human origin.

AB - Tumor necrosis factor-a (TNF-a) has widespread metabolic actions. Systemic TNF-a administration, however, generates a complex hormonal and metabolic response. Our study was designed to test whether regional, placebo-controlled TNF-a infusion directly affects insulin resistance and protein breakdown. We studied eight healthy volunteers once with bilateral femoral vein and artery catheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp. One artery was perfused with saline and one with TNF-a. During the clamp, TNF-a perfusion increased glucose arteriovenous differences (0.91 6 0.17 vs. 0.74 6 0.15 mmol/L, P = 0.012) and leg glucose uptake rates. Net phenylalanine release was increased by TNF-a perfusion with concomitant increases in appearance and disappearance rates. Free fatty acid kinetics was not affected by TNF-a, whereas interleukin-6 (IL-6) release increased. Insulin and protein signaling in muscle biopsies was not affected by TNF-a. TNF-a directly increased net muscle protein loss, which may contribute to cachexia and general protein loss during severe illness. The finding of increased insulin sensitivity, which could relate to IL-6, is of major clinical interest and may concurrently act to provide adequate tissue fuel supply and contribute to the occurrence of systemic hypoglycemia. This distinct metabolic feature places TNF-a among the rare insulin mimetics of human origin.

U2 - 10.2337/db13-0138

DO - 10.2337/db13-0138

M3 - Journal article

C2 - 23835341

SN - 0012-1797

VL - 62

SP - 4023

EP - 4029

JO - Diabetes

JF - Diabetes

IS - 12

ER -